Skip to content
Search

Latest Stories

Vaccine-preventable infections costing UK billions

Vaccine-preventable infections costing UK billions

Effective interventions are needed to prevent hospitalisations

Effective interventions are having a positive impact but more needs to be done to combat vaccine-preventable infections after data revealed today showed that it accounted for 20 per cent of hospital bed usage in the UK between 2023 to 2024 at a cost of almost £6 billion.

The return of social mixing, international travel and migration following the COVID-19 pandemic have contributed to the rise in both endemic disease and vaccine-preventable infections, according to the UK Health Security Agency's (UKHSA).


The report showed some positive impact in some areas due to the increase in vaccination with community pharmacies playing an important part in the take up vaccines.

In COVID-19, for example, transmission has declined, with the virus circulating at baseline levels of activity for much of the current winter season. The reported highlighted that vaccination of priority groups, in particular the elderly, remained an important intervention to protect against severe disease.

“We have also seen vaccine uptake decrease for a number of infectious diseases, including measles, whooping cough and in certain groups eligible for the flu vaccine, such as under 65 at risk, pregnant women and health care workers,” said Richard Pebody, director of epidemic and emerging infections at UKHSA.

“This winter has demonstrated that rises in rates of infectious diseases can cause significant strain, not only on the individuals directly affected, but also on the NHS. It is vital that we are not complacent about infections where we can reduce the burden of disease via interventions such as our world-class vaccination programmes.”

The most deprived areas saw diseases and infections twice as high compared to the least deprived with the UKHSA is undertaking further work to better understand these disparities.

“Our scientific capability and the introduction of new interventions are all helping to keep people safe and well, but our report also highlights that we have plenty of work and opportunities ahead,” said dame Jenny Harries, chief executive of the UKHSA.

“Along with our partners across the healthcare sector, we need to be bolder. Behind this data there are real people, people who are sick or at risk of becoming sick, and in some cases dying. This brings with it a cost to our economy too. Yet much of this harm and distress is preventable.

“Our rich data sources provide us with a huge amount of knowledge, and we will continue to use it, carefully and confidentially, to reduce the burden of infectious disease across the country, ensuring our interventions reach the people who need them most.”

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less